Profile data is unavailable for this security.
About the company
Wanbury Limited is an India-based pharmaceutical company having a presence in active pharmaceutical ingredients (APIs) global market and domestic branded formulations. It is engaged in the business of pharmaceutical and related activities, including research. Its API products include metformin, metformin dc, tramadol, sertraline, diphenhydramine hcl, diphenhydramine citrate, mefenamic acid, paroxetine hemihydrate, promethazine, glucosamine, clopidogrel, levetiracetam and carvedilol phosphate monohydrate. In formulations, the Company has a presence across various therapeutic categories, such as cough and cold solutions, gynecology, orthopedics, nutraceuticals, gastrointestinal, anti-inflammatory and analgesics. The Company is also focused on development of products like ketamine, rivaroxaban, montelukast, sitagliptin and few others to reduce dependency on metformin and sertraline. The Company has USFDA and EUGMP approved facilities at Tanuku, Andra Pradesh, and Patalganga, Maharashtra.
- Revenue in INR (TTM)5.60bn
- Net income in INR523.05m
- Incorporated1988
- Employees1.49k
- LocationWanbury Ltd'B' Wing, 10th Floor, BSEL TechparkOpp. Vashi Railway Station, Sector 30AVashiNAVI MUMBAI 400703IndiaIND
- Phone+91 2 267942222
- Fax+91 2 267942111
- Websitehttp://www.wanbury.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medicamen Biotech Ltd | 1.80bn | 81.05m | 5.65bn | 378.00 | 55.08 | -- | 41.83 | 3.13 | 8.11 | 8.11 | 160.31 | -- | -- | -- | -- | 4,772,797.00 | -- | 5.89 | -- | 8.45 | 46.89 | 36.54 | 3.52 | 9.58 | -- | 2.79 | -- | 8.46 | 27.29 | 7.90 | -26.36 | -1.89 | -16.71 | 0.00 |
| Accent Microcell Ltd | 2.45bn | 301.68m | 5.77bn | 174.00 | 14.67 | 3.52 | 16.67 | 2.35 | 18.67 | 18.67 | 126.45 | 77.86 | -- | -- | -- | 14,109,070.00 | -- | -- | -- | -- | 31.00 | -- | 12.29 | -- | 3.42 | -- | 0.0724 | -- | 24.45 | -- | 146.63 | -- | -- | -- |
| Kilitch Drugs (India) Ltd | 1.51bn | 125.85m | 5.94bn | 168.00 | 47.06 | -- | 42.30 | 3.93 | 7.85 | 7.85 | 94.36 | -- | -- | -- | -- | 9,003,994.00 | -- | 3.38 | -- | 4.76 | 36.87 | 35.33 | 7.03 | 6.17 | -- | 2.63 | -- | 0.00 | 10.58 | 13.35 | 39.75 | 30.69 | -19.45 | -- |
| Sakar Healthcare Ltd | 1.56bn | 112.43m | 7.14bn | 325.00 | 63.16 | -- | 23.95 | 4.59 | 5.20 | 5.20 | 71.95 | -- | -- | -- | -- | 4,784,942.00 | -- | 5.26 | -- | 6.28 | 45.62 | 43.47 | 7.22 | 10.12 | -- | 3.10 | -- | -- | 14.99 | 17.58 | -8.53 | 11.76 | 19.05 | -- |
| IND Swift Laboratories Ltd | 10.04bn | 4.05bn | 7.95bn | 47.00 | 1.96 | -- | 1.79 | 0.7925 | 68.53 | 68.53 | 170.41 | -- | -- | -- | -- | 213,559,000.00 | -- | 5.00 | -- | 6.13 | 47.54 | 41.12 | 40.36 | 8.52 | -- | 4.68 | -- | 0.00 | 6.10 | 11.10 | 784.44 | 70.82 | 23.60 | -- |
| Albert David Ltd | 3.60bn | 707.73m | 8.33bn | 1.50k | 11.77 | -- | 10.74 | 2.31 | 124.02 | 124.02 | 630.61 | -- | -- | -- | -- | 2,403,949.00 | -- | 10.00 | -- | 13.15 | 65.26 | 59.85 | 19.67 | 11.87 | -- | 83.07 | -- | 12.89 | 6.12 | 2.72 | 108.49 | 33.59 | 40.87 | 13.90 |
| Wanbury Ltd | 5.60bn | 523.05m | 8.69bn | 1.49k | 17.09 | -- | 13.29 | 1.55 | 15.54 | 15.54 | 168.35 | -- | -- | -- | -- | 3,759,038.00 | -- | 11.63 | -- | -- | 49.35 | 42.46 | 9.33 | 7.62 | -- | 1.76 | -- | -- | 15.21 | 8.02 | 638.26 | -- | 29.87 | -- |
| Nectar Lifesciences Ltd | 16.49bn | 61.44m | 9.89bn | 1.69k | 160.27 | -- | 14.76 | 0.5994 | 0.275 | 0.275 | 73.96 | -- | -- | -- | -- | 9,782,218.00 | -- | -0.2956 | -- | -0.541 | 29.64 | 16.49 | 0.3725 | -0.4053 | -- | 1.06 | -- | -- | 10.53 | -9.56 | 120.66 | -36.29 | -5.06 | -- |
| Jagsonpal Pharmaceuticals Ltd | 2.10bn | 203.13m | 10.71bn | 1.03k | 53.48 | -- | 47.26 | 5.10 | 7.57 | 7.57 | 78.03 | -- | -- | -- | -- | 2,048,663.00 | -- | 10.95 | -- | 13.29 | 56.41 | 58.13 | 9.67 | 9.21 | -- | 26.27 | -- | 43.81 | -11.83 | 4.58 | -15.94 | 25.50 | -35.69 | 82.06 |
